Investor Information

Development Status (Development Pipeline)

This is the development status as of Jul 24, 2020.
Development Status (As of the latest Announcement of business results) (1.3MB)



Oncology (OPDIVO)

As of Jul 24, 2020

The table below can be viewed by scrolling horizontally.

Product name
(Generic name)
Mechanism Target disease Development stage Country/
Region
Licensor
T U V F
i
l
i
n
g
A
p
p
r
o
v
a
l
Opdivo Injection (Nivolmub) Anti-PD-1 antibody Melanoma(1st) JPEKRETW In-house
(Co-developed with Bristol Myers Squibb)
Melanoma (Adjuvant therapy) JPEKRETW
Non-small cell lung cancer (2nd`) JPEKRETW
Non-small cell lung cancer (1st) JP
Non-small cell lung cancer (1st) KRETW
Renal cell carcinoma (2nd`) JPEKRETW
Renal cell carcinoma (1st) JPEKRETW
Hodgkin’s lymphoma JPEKRETW
Head and neck cancer JPEKRETW
Gastric cancer (3rd) JPEKRETW
Gastric cancer (1st) JP
Gastric cancer (1st) KRETW
Malignant pleural mesothelioma JP
Colorectal canceriMSI-Highj JPETW
Esophageal cancer JPEKRETW
Gastro-esophageal junction cancer and esophageal cancer JPEKRETW
Small cell lung cancer JPEKRETW
Hepatocellular carcinoma JPEKR
Hepatocellular carcinoma TW
Glioblastoma JP
Urothelial cancer JP
Urothelial cancer KRETW
Ovarian cancer JPEKRETW
Bladder cancer JPEKRETW
Cervix carcinoma, Uterine body cancer, Soft tissue sarcoma JP
Central nervous system lymphoma, Primary Testicular Lymphoma JP
Pancreatic cancer JPEKRETW
Virus positive/negative solid carcinoma JPEKRETW
Biliary tract cancer JP
Prostate cancer JPEKRETW

Oncology (Other than OPDIVO)

As of Jul 24, 2020

The table below can be viewed by scrolling horizontally.

Product name
(Generic name)
Mechanism Target disease Development stage Country/
Region
Licensor
T U V F
i
l
i
n
g
A
p
p
r
o
v
a
l
Yervoy Injection (Ipilimumab) Anti-CTLA-4 antibody Melanoma JPEKRETW BMS
Renal cell carcinoma JPEKRETW
Non-small cell lung cancer JP
Non-small cell lung cancer KRETW
Colorectal canceriMSI-Highj JP
Colorectal canceriMSI-Highj TW
Small cell lung cancer JPEKRETW
Head and neck cancer JPEKRETW
Gastric cancer JPEKRETW
Malignant pleural mesothelioma JP
Esophageal cancer JPEKRETW
Urothelial cancer JPEKRETW
Hepatocellular carcinoma JPEKRETW
Virus positive/negative solid carcinoma JPEKRETW
ONO-4059/ (Tirabrutinib) Bruton‘s tyrosine kinase (BTK) inhibitor Primary central nervous system lymphoma JP In-house
Primary macroglobulinemia Lymphoplasmacytic lymphoma JP
ONO-7643/ (Anamorelin) Ghrelin mimetic Cancer cachexia JP Helsinn
Braftovi Capsule/ (Encorafenib) BRAF inhibitor Melanoma (BRAF-mutation positive) JP Pfizer
KR
Colorectal cancer (BRAF-mutation positive) JP
KR
Mektovi Tablet/ (Binimetinib) MEK inhibitor Melanoma (BRAF-mutation positive) JP Pfizer
KR
Colorectal cancer (BRAF-mutation positive) JP
KR
Kyprolis Injection/ (Carfilzomib) Proteasome inhibitor Multiple myeloma JP Amgen
ONO-7701
iLinrodostatj
IDO1 inhibitor Bladder cancer JPEKRETW BMS
ONO-7912 (Devimistat) Cancer metabolism inhibitor Pancreatic cancer KR Rafael
JP
Acute myeloid leukemia KR
ONO-4687 (Cabiralizumab) Anti-CSF-1R antibody Pancreatic cancer JPEKRETW BMS
ONO-4686 Anti-TIGIT antibody Solid tumor JP BMS
ONO-7807 Anti-TIM-3 antibody Solid tumor JP BMS
ONO-4482 (Relatlimab) Anti-LAG-3 antibody Melanoma JP BMS
ONO-4483 (Lirilumab) Anti-KIR antibody Solid tumor JP BMS
ONO-4578 PG receptor (EP4) antagonist Solid tumor JP In-house
ONO-7475 Axl/Mer inhibitor Solid tumor JP In-house
Acute leukemia US In-house
ONO-7911 (Bempegaldesleukin) PEGylated IL-2 Solid tumor JP BMS
ONO-7913 (Magrolimab) Anti-CD47 mAb Solid tumor JP Gilead

Combination with Opdivo.

Areas other than Oncology

As of Jul 24, 2020

The table below can be viewed by scrolling horizontally.

Product name
(Generic name)
Mechanism Target disease Development stage Country/
Region
Licensor
T U V F
i
l
i
n
g
A
p
p
r
o
v
a
l
Coralan Tablet/ ONO-1162 (Ivabradine) HCN channel blocker Chronic heart failure JP Servier
Ongentys Capsule/ ONO-2370 (Opicapone) Long acting COMT inhibitor Parkinson’s disease JP Bial
Onoact Injection (Landiolol hydrochloride) Short-active selective 1 blocker Tachyarrhythmia associated with sepsis JP In-house
Tachyarrhythmia in low cardiac function (Pediatric) JP
ONO-5704/SI-613 Hyaluronic acid-NSAID Osteoarthritis JP Seikagaku
Enthesopathy JP
Orencia SC (Abatacept) T-cell activation inhibitor Prevention of structural damage of joints in rheumatoid arthritis JP BMS
Polymyositis/ Dermatomyositis JP
Velexbru Tablet/ ONO-4059 (Tirabrutinib) Bruton's tyrosine kinase (BTK) inhibitor Pemphigus JP In-house
ONO-7269 FXIa inhibitor Cerebral infarction JP In-house
ONO-4685 PD-1~CD3 bispecific antibody Autoimmune disease JP In-house
ONO-2808 S1P5 receptor agonist Neurodegenerative disease EU In-house
ONO-7684 FXIa inhibitor Thrombosis EU In-house
ONO-2910 Enhancement of Schwann cell differentiation Peripheral nerve disorder JP In-house
FOIPAN Protease enzyme inhibitor Novel coronavirus infection (COVID-19) JP In-house